Highlights of June 2023
1.
Lupin receives $25 Million from AbbVie as a part
of a strategic partnership to initiate Lupin’s novel MALT1 inhibitor program
clinical trial.
2.
Laurus Labs invests Rs 80 crore(~$10 Million) in
cell & gene therapy firm ImmunoACT.
3. iNova to buy Mundipharma's consumer
healthcare brands for $540 million.
4.
Corona Remedies acquires Myoril brand from
Sanofi.
5.
Zydus acquires 6.5% equity stake in Indian
biotech company Mylab.
6.
Vieroots announces collaboration with AliveCor
to enable ECG monitoring in 30 secs.
7.
Lupin, Enzene Biosciences announce strategic
collaboration to launch Cetuximab in India.
8.
Portea, AliveCor, and NanoHealth collaborates to
launch HeartSmart app to provide cardiac care.
9.
Nova IVF acquires Ahmedabad company Wings to
expand its presence in Gujarat.
10. Aurobindo
Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug.
11. Getinge to acquire High Purity New
England.
12. Australia's Telix Pharma enters to acquire
UK-based medical device firm Lightpoint Medical(Upfront equity payment of $20
million, and an additional earn-out payment of $15 million on completion of
certain milestones).
Highlights at Aagami:
1. New Client: Global Medical company from Israel has awarded Aagami a Market
Landscape research assignment.
2. Aagami brought 2 licensing term sheets for its Pain
Asset client.
3. Aagami successfully completed BIO International
Convention 2023 (June 5-8) with 45+ meetings. The event turned out to be the
best ever BIO International Convention for Aagami.
|
INFOCUS: Select opportunities available at Aagami:
|
|
|
|
|
|
For Partnering/Licensing/ Co-development:
- Licensing/Co-development: Easy to apply world’s First Transdermal
Tizanidine Patch for the Management of Spasticity. Impressive
Phase 1 results. Ready to initiate Phase 2.
- Licensing for US
available: Lidocaine 10% Topical Patch; NDA approval expected in Q4
of 2023. Made using Proprietary drug formulation
technology, ILTS® (Ionic Liquid Transdermal Technology).
Indication: the treatment of PHN (postherpetic neuralgia)
- Seeking Partnering/JV – Phase 2 Smart Drug
preventing Myelodysplastic Syndromes (MDS) from advancing to
full-scale myelogenous Leukemia.
- Seeking
licensing/co-development partnerships: A single (monovalent)
vaccine for Targeting Salmonella, ETEC / E. coli,
Campylobacter, Shigella. Fulfills an unmet need for treating
Bacterial Dysentery.
For Acquisition:
- Available at a very
reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology,
product candidates, data package of ~20 drug candidates, IP etc.-
for Next-generation biologics and substantial returns.
- Asset Sale/Licensing - Oral small molecule
modulator of mutant RyR2 for the treatment of CPVT-1/ Heart
Arrhythmia.
Seeking Investment:
- Seeking US$5 million: A single (monovalent)
vaccine for Targeting Salmonella, ETEC / E. coli,
Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial
Dysentery.
- $40 Million Series C: On the market, US FDA
approved novel portable MRI Guided Treatment, Diagnosis and
Screening, for Urology applications. California based client.
- Seeking US$200K: Precision
fermentation-based technology to produce Natural Soluble Melanin at
a cost hundreds of times lower. The current round
proceeds will be used to achieve milestone of making a market
ready Sunscreen cream using Melanin, under Consumer Health &
Wellness category.
- Seeking US$25 million: Midwest US based Pharma
First-in-Class Non-Opioid Analgesic for Pain Relief. Just $4
Million further needed to complete next milestone.
|
|
|
|